Luca Zammataro

Texas Medical Center — United States

Medicine · Health Sciences

35h-index4.7kcitations137works1.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HER2/EGFR in Cancer Research(21), Protein Degradation and Inhibitors(20), Cancer Genomics and Diagnostics(19), Chromatin Remodeling and Cancer(17), Estrogen and related hormone effects(14)

Publications137 total

Simultaneous high-throughput identification of myeloid leukemia driver mutation-derived public neoantigens and cognate functional TCRs for TCR-T therapy
Blood·2025
Cancer-associated VEGFR2R1032Q sustains receptor activation also by promoting ligand-independent hetero-dimerization with co-expressed wild-type VEGFR2 and translocation into lipid rafts
Neoplasia·2025· 3 citedOpen Access
Biophysical modeling for accurate T cell specificity prediction of viral and tumor antigens
2025Open Access
157 Simultaneous high-throughput identification of driver mutation-derived public neoantigens and cognate functional T cell receptors
Regular and Young Investigator Award Abstracts·2024Open Access
CINNAMON-GUI: Revolutionizing Pap Smear Analysis with CNN-Based Digital Pathology Image Classification
F1000Research·2024· 2 citedOpen Access
Editorial Expression of Concern: Class 3 semaphorins control vascular morphogenesis by inhibiting integrin function
Nature·2024
Supplementary Figure 1 from <i>In Vitro</i> and <i>In Vivo</i> Activity of IMGN853, an Antibody–Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers
2023Open Access
Supplementary Figure 2 from <i>In Vitro</i> and <i>In Vivo</i> Activity of IMGN853, an Antibody–Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers
2023Open Access
Data from Dual-Targeting Nanoparticles for <i>In Vivo</i> Delivery of Suicide Genes to Chemotherapy-Resistant Ovarian Cancer Cells
2023Open Access
Supplementary Table 2 from <i>In Vitro</i> and <i>In Vivo</i> Activity of IMGN853, an Antibody–Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers
2023Open Access
Supplementary Table 1 from <i>In Vitro</i> and <i>In Vivo</i> Activity of IMGN853, an Antibody–Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers
2023Open Access
Data from Dual-Targeting Nanoparticles for <i>In Vivo</i> Delivery of Suicide Genes to Chemotherapy-Resistant Ovarian Cancer Cells
2023Open Access
Data from <i>In Vitro</i> and <i>In Vivo</i> Activity of IMGN853, an Antibody–Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers
2023Open Access
Supplementary Table 2 from <i>In Vitro</i> and <i>In Vivo</i> Activity of IMGN853, an Antibody–Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers
2023Open Access
Supplementary Figure 3 from <i>In Vitro</i> and <i>In Vivo</i> Activity of IMGN853, an Antibody–Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers
2023Open Access
Supplementary Figure 2 from <i>In Vitro</i> and <i>In Vivo</i> Activity of IMGN853, an Antibody–Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers
2023Open Access
Data from <i>In Vitro</i> and <i>In Vivo</i> Activity of IMGN853, an Antibody–Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers
2023Open Access
Supplementary Figure 3 from <i>In Vitro</i> and <i>In Vivo</i> Activity of IMGN853, an Antibody–Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers
2023Open Access
Supplementary Figure 1 from <i>In Vitro</i> and <i>In Vivo</i> Activity of IMGN853, an Antibody–Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers
2023Open Access
Supplementary Table 1 from <i>In Vitro</i> and <i>In Vivo</i> Activity of IMGN853, an Antibody–Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers
2023Open Access
page 1 of 7Next →

Frequent Co-authors

Stefania Bellone(26), Peter E. Schwartz(26), Alessandro D. Santin(26), Elena Ratner(25), Elena Bonazzoli(24), Masoud Azodi(24), Gulden Menderes(23), Gary Altwerger(21), Natália Buza(19), Pei Hui(19), Dan‐Arin Silasi(18), Gloria S. Huang(17), Salvatore Lopez(15), Burak Zeybek(13), Chanhee Han(13), Aránzazu Manzano(12), Anna Bianchi(12), Babak Litkouhi(12), Paola Manara(11), Francesca Pettinella(10)